Drug intelligence / Profile preview

HFG3

Development stage: Preclinical
Lead developer: HighField Biopharmaceuticals
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

HFG3 is a small interfering RNA (siRNA) therapeutic in preclinical development for the treatment of metabolic diseases. It is being developed by Hangzhou Gaotian Biomedical and also appears in the pipeline of HighField as an siRNA-based therapy for metabolic disease. The precise molecular target and mechanism of action have not been publicly disclosed, but as an siRNA, it likely functions by silencing specific gene expression relevant to metabolic pathways. Its primary indication area is endocrinology and metabolic disease[1][4].

Beyond the preview

Go deeper on HFG3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HFG3.

Explore the full profile